Orphan drugs are a fascinating area for potential investment -- they command premium pricing, treat niche diseases, and often have extended patent protection since they're so specialized.
And while this area of the market is speculative, the opportunities are enormous. And there are ways to mitigate your risk, particularly by investing in companies with broad pipelines (or a single drug that has already proven commercially successful).
In the video below, health care analysts Michael Douglass and David Williamson lay out why investors should be watching Alexion (NASDAQ:ALXN), Shire (NASDAQ:SHPG), and ISIS (NASDAQ:IONS) in this exciting and innovative corner of the market.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.